Pliant Therapeutics has pumped the breaks on a midstage trial of its lead lung disease drug on the advice of its safety committee. The South San Francisco biotech has been evaluating 160-mg and ...

Pliant Therapeutics paused enrollment in its BEACON-IPF Phase 2b trial of bexotegrast after a safety board review. Get real-time earnings alerts before the market moves and access expert analysis ...

A clinical study testing a Pliant Therapeutics drug once considered a promising prospect for treating a fatal lung disorder is now on pause at the recommendation of independent outside observers.

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report). The company’s shares closed last Friday at $7.79. Leverage the ...

A committee of clinical trial monitors has advised Pliant Therapeutics to stop giving its experimental fibrosis drug to patients in a Phase 2 trial, seeding doubt about the therapy’s future.

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations, causing significant stock volatility. High trading volumes and sharp ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board, the company has voluntarily paused ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX), a biotechnology company focused on fibrotic diseases with a market capitalization of $674 million, has named Delphine Imbert ...

Kodak Black has three sons, King Khalid, Prince and Prince Vulture and two daughters, Queen Yuri and Princess Isabella Ann Emily Blackwood is a writer and editor at PEOPLE. She has been working at ...